Boston Scientific completes $3.7B acquisition of Axonics

Boston Scientific/Axonics sacral neuromodulation (R20 / F15)

Boston Scientific finalized its acquisition of Axonics, Inc. for $71 per share in cash, representing an equity value of $3.7 billion and an enterprise value of $3.3 billion. Axonics specializes in sacral neuromodulation devices for bladder and bowel dysfunction, including the rechargeable R20 and the recharge-free F15 systems.

• Purchase price: $71 per share; equity value $3.7B, enterprise value $3.3B net of cash.
• Axonics R20 and F15 systems treat overactive bladder, urinary retention, and fecal incontinence.
• R20 functional life ≥20 years, recharged every 6–10 months; F15 lasts ≥15 years without recharging.
• Transaction expected immaterial to adjusted EPS in 2024–2025, accretive thereafter.